Literature DB >> 8756566

Multimeric complex formation by the thyrotropin receptor in solubilized thyroid membranes.

P N Graves1, H Vlase, Y Bobovnikova, T F Davies.   

Abstract

The TSH receptor (TSHR) has a large glycosylated ectodomain comprising the amino-terminal half of the molecule (394 of 743 residues) implicated in TSH binding, as well as autoantibody recognition in Graves' disease. In this study we employed antibodies specific for the amino-terminus (Ab1), midportion (Ab2), and carboxyl-terminus (Ab3) of the TSHR-ectodomain, previously mapped using recombinant receptor proteins, to detect the natural receptor present in detergent-solubilized porcine thyroid cell membranes via immunoblotting. Several forms of the receptor were detected. In reduced samples Ab1 detected full-length holoreceptors present in both nonglycosylated and glycoslylated forms of apparent molecular masses 80 and 90 kDa, respectively, as well as apparent dimeric nonglycosylated and dimeric glycosylated holoreceptor forms resistant to reduction. Also detected by Ab1 were a glycosylated amino-terminal 47- to 52-kDa fragment of the holoreceptor (gly alpha-subunit), reduced to 42 kDa (alpha-subunit) by Endo F deglycosylation. Ab2 detected all of the same forms. Ab3 detected primarily a carboxy-terminal, nonglycosylated fragment of 35 kDa (beta-subunit). In unreduced samples, the recognition pattern was unchanged with Ab1. Ab2 detected monomeric and dimeric beta-subunits, as well as higher order complexes. The different TSHR forms present in unreduced preparations were resolved by ammonium sulfate precipitation, confirming their autonomy. The data demonstrate the presence of multiple forms of the natural TSHR. Their roles in TSH action and TSHR autoimmunity require further exploration.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8756566     DOI: 10.1210/endo.137.9.8756566

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  15 in total

1.  Cleavage of the thyrotropin receptor.

Authors:  N M Islam; C L Hew; V Kaczur; N R Farid
Journal:  J Endocrinol Invest       Date:  2001-11       Impact factor: 4.256

Review 2.  The TSH receptor reveals itself.

Authors:  Terry Davies; Russell Marians; Rauf Latif
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

3.  Transmembrane domains of attraction on the TSH receptor.

Authors:  Rauf Latif; M Rejwan Ali; Mihaly Mezei; Terry F Davies
Journal:  Endocrinology       Date:  2014-11-19       Impact factor: 4.736

Review 4.  The genetics of the thyroid stimulating hormone receptor: history and relevance.

Authors:  Terry F Davies; Xiaoming Yin; Rauf Latif
Journal:  Thyroid       Date:  2010-07       Impact factor: 6.568

5.  Evidence that the thyroid-stimulating hormone (TSH) receptor transmembrane domain influences kinetics of TSH binding to the receptor ectodomain.

Authors:  Chun-Rong Chen; Sandra M McLachlan; Basil Rapoport
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

6.  A Modifying Autoantigen in Graves' Disease.

Authors:  Rauf Latif; Mihaly Mezei; Syed A Morshed; Risheng Ma; Rachel Ehrlich; Terry F Davies
Journal:  Endocrinology       Date:  2019-05-01       Impact factor: 4.736

7.  Subunit interactions influence TSHR multimerization.

Authors:  Rauf Latif; Krzysztof Michalek; Terry F Davies
Journal:  Mol Endocrinol       Date:  2010-08-18

Review 8.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease.

Authors:  Terry F Davies; Takao Ando; Reigh-Yi Lin; Yaron Tomer; Rauf Latif
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

9.  A tyrosine residue on the TSH receptor stabilizes multimer formation.

Authors:  Rauf Latif; Krzysztof Michalek; Syed Ahmed Morshed; Terry F Davies
Journal:  PLoS One       Date:  2010-02-26       Impact factor: 3.240

Review 10.  Novel insights on thyroid-stimulating hormone receptor signal transduction.

Authors:  Gunnar Kleinau; Susanne Neumann; Annette Grüters; Heiko Krude; Heike Biebermann
Journal:  Endocr Rev       Date:  2013-05-03       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.